KR20120068878A - 니코틴성 아세틸콜린 수용체 알파 7 활성화제의 용도 - Google Patents

니코틴성 아세틸콜린 수용체 알파 7 활성화제의 용도 Download PDF

Info

Publication number
KR20120068878A
KR20120068878A KR1020127007287A KR20127007287A KR20120068878A KR 20120068878 A KR20120068878 A KR 20120068878A KR 1020127007287 A KR1020127007287 A KR 1020127007287A KR 20127007287 A KR20127007287 A KR 20127007287A KR 20120068878 A KR20120068878 A KR 20120068878A
Authority
KR
South Korea
Prior art keywords
agonist
nachr
levodopa
parkinson
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020127007287A
Other languages
English (en)
Korean (ko)
Inventor
테레제 디 파올로
도미니크 포이어바흐
발타자르 고메즈-만실라
도날드 존스
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42990156&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20120068878(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20120068878A publication Critical patent/KR20120068878A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020127007287A 2009-09-22 2010-09-22 니코틴성 아세틸콜린 수용체 알파 7 활성화제의 용도 Ceased KR20120068878A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24465809P 2009-09-22 2009-09-22
US61/244,658 2009-09-22

Publications (1)

Publication Number Publication Date
KR20120068878A true KR20120068878A (ko) 2012-06-27

Family

ID=42990156

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127007287A Ceased KR20120068878A (ko) 2009-09-22 2010-09-22 니코틴성 아세틸콜린 수용체 알파 7 활성화제의 용도

Country Status (22)

Country Link
US (3) US10537539B2 (https=)
EP (1) EP2480228B1 (https=)
JP (2) JP6178074B2 (https=)
KR (1) KR20120068878A (https=)
CN (1) CN102573830A (https=)
AU (1) AU2010299967B2 (https=)
BR (1) BR112012006346A2 (https=)
CA (1) CA2774801C (https=)
CL (1) CL2012000702A1 (https=)
EA (1) EA036742B1 (https=)
ES (1) ES2614930T3 (https=)
IL (1) IL218299A (https=)
JO (1) JO3250B1 (https=)
MA (1) MA33590B1 (https=)
MX (1) MX359011B (https=)
NZ (1) NZ598316A (https=)
PH (1) PH12012500554A1 (https=)
SG (1) SG178832A1 (https=)
TN (1) TN2012000082A1 (https=)
TW (1) TWI558398B (https=)
WO (1) WO2011036167A1 (https=)
ZA (1) ZA201201066B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101879919B1 (ko) * 2013-01-15 2018-07-18 노파르티스 아게 알파 7 니코틴성 아세틸콜린 수용체 작용물질의 용도

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
JO3250B1 (ar) * 2009-09-22 2018-09-16 Novartis Ag إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7
AR081402A1 (es) 2010-05-17 2012-08-29 Envivo Pharmaceuticals Inc Una forma cristalina de clorhidrato de (r)-7-cloro-n-(quinuclidin-3-il) benzo(b)tiofeno-2-carboxamida monohidrato
KR20140003580A (ko) * 2011-01-27 2014-01-09 노파르티스 아게 니코틴성 아세틸콜린 수용체 알파 7 활성화제의 용도
SG192078A1 (en) 2011-02-03 2013-08-30 Lupin Ltd Pyrrole derivatives used as modulators of alpha7 nachr
ES2594409T3 (es) 2011-02-23 2016-12-20 Lupin Limited Derivados de heteroarilo como moduladores del nAChR á7
WO2012127393A1 (en) * 2011-03-18 2012-09-27 Novartis Ag COMBINATIONS OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATORS AND mGluR5 ANTAGONISTS FOR USE IN DOPAMINE INDUCED DYSKINESIA IN PARKINSON'S DISEASE
WO2012131576A1 (en) 2011-03-31 2012-10-04 Lupin Limited Pyrrole derivatives as nicotinic acetylcholine receptor modulators for use in the treatment of neurodegenerative disorders such as alzheimer's and parkinson's disease
EP2729455B1 (en) 2011-07-05 2016-09-14 Lupin Limited Biaryl derivatives as nachr modulators
JP6162705B2 (ja) * 2011-10-20 2017-07-12 ノバルティス アーゲー アルファ７ニコチン性アセチルコリン受容体活性化剤による処置に対する応答性を予測するバイオマーカー
NZ629453A (en) 2012-03-06 2016-04-29 Lupin Ltd Thiazole derivatives as alpha 7 nachr modulators
CA2872005A1 (en) 2012-05-08 2013-11-14 Forum Pharmaceuticals, Inc. Methods of maintaining, treating or improving cognitive function
US8729263B2 (en) 2012-08-13 2014-05-20 Novartis Ag 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions
US20150299178A1 (en) 2012-11-12 2015-10-22 Lupin Limited Thiazole Derivatives as Alpha 7 NACHR Modulators
EP2945633B1 (en) * 2013-01-15 2021-06-30 Novartis AG Use of alpha 7 nicotinic acetylcholine receptor agonists
US20150313884A1 (en) 2013-01-15 2015-11-05 Novartis Ag Use of alpha 7 nicotinic acetylcholine receptor agonists
US9617211B2 (en) 2013-01-16 2017-04-11 Lupin Limited Pyrrole derivatives as alpha 7 nAChR modulators
US9617210B2 (en) 2013-03-13 2017-04-11 Lupin Limited Pyrrole derivatives as alpha 7 NACHR modulators
TW201446243A (zh) 2013-06-03 2014-12-16 Lupin Ltd 4-(5-(4-氯苯基)-2-(2-環丙基乙醯基)-1,4-二甲基-1氫-吡咯-3-基)苯磺醯胺作為α7尼古丁乙醯膽鹼受體調節劑
AU2014282886A1 (en) 2013-06-17 2015-12-17 Lupin Limited Pyrrole derivatives as alpha 7 nAChR modulators
EP4105208A1 (en) * 2013-07-31 2022-12-21 Novartis AG 1,4-disubstituted pyridazine derivatives and their use for treating smn-deficiency-related conditions
US20150313891A1 (en) * 2014-05-02 2015-11-05 Abbvie Inc. Neuronal nicotinic agonists and methods of use
CA2960644C (en) 2014-09-09 2021-06-29 Merial, Inc. Mammalian cell lines expressing functional nematode acetylcholine receptors and use thereof for high-throughput screening assays
WO2016100184A1 (en) 2014-12-16 2016-06-23 Forum Pharmaceuticals, Inc. Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors
MX2017016231A (es) 2015-06-10 2018-11-29 Axovant Sciences Gmbh Compuestos de aminobencisoxazol como agonistas de receptores a7-nicotínicos de acetilcolina.
WO2017027600A1 (en) 2015-08-12 2017-02-16 Forum Pharmaceuticals, Inc. GEMINAL SUBSTITUTED AMINOBENZISOXAZOLE COMPOUNDS AS AGONISTS OF α7-NICOTINIC ACETYLCHOLINE RECEPTORS
CA3002801A1 (en) * 2015-10-20 2017-04-27 Axovant Sciences Gmbh Aminoisoxazoline compounds as agonists of alpha7-nicotinic acetylcholine receptors
JP7312749B2 (ja) 2017-08-04 2023-07-21 スカイホーク・セラピューティクス・インコーポレーテッド スプライシングをモジュレートする方法および組成物
WO2020163405A1 (en) 2019-02-05 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
JP7551629B2 (ja) 2019-02-05 2024-09-17 スカイホーク・セラピューティクス・インコーポレーテッド スプライシングを調節するための方法および組成物
JP7603594B2 (ja) 2019-02-06 2024-12-20 スカイホーク・セラピューティクス・インコーポレーテッド スプライシングを調節するための方法および組成物
JP7603595B2 (ja) 2019-02-06 2024-12-20 スカイホーク・セラピューティクス・インコーポレーテッド スプライシングを調節するための方法および組成物

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566368B2 (en) 1994-04-22 2003-05-20 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage form for ameliorating male erectile dysfunction
US5990168A (en) 1996-04-18 1999-11-23 Alberta Cancer Board Methods and compositions for the treatment of ataxia telangiectasia
US7214686B2 (en) * 1997-06-30 2007-05-08 Targacept, Inc. Pharmaceutical compositions and methods for effecting dopamine release
US6908631B1 (en) * 1997-12-01 2005-06-21 Nicogen, Inc. Therapeutic and diagnostic methods dependent on CYP2A enzymes
US6953855B2 (en) 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
US6432975B1 (en) 1998-12-11 2002-08-13 Targacept, Inc. Pharmaceutical compositions and methods for use
CA2393437C (en) 1998-12-16 2009-12-15 University Of South Florida Exo-s-mecamylamine formulation and use in treatment
FR2804430B1 (fr) 2000-01-28 2002-03-22 Sanofi Synthelabo Derives de 4-heteroaryl-1,4-diazabicyclo[3.2.2] nonane, leur preparation et leur application en therapeutique
GB0010955D0 (en) 2000-05-05 2000-06-28 Novartis Ag Organic compounds
AR036041A1 (es) * 2001-06-12 2004-08-04 Upjohn Co Compuestos aromaticos heterociclicos sustituidos con quinuclidina y composiciones farmaceuticas que los contienen
DE10156719A1 (de) 2001-11-19 2003-05-28 Bayer Ag Heteroarylcarbonsäureamide
GB0128996D0 (en) 2001-12-04 2002-01-23 Novartis Ag Organic compounds
DE10211415A1 (de) 2002-03-15 2003-09-25 Bayer Ag Bicyclische N-Biarylamide
DE10211416A1 (de) 2002-03-15 2003-09-25 Bayer Ag Essig- und Propionsäureamide
SE0201943D0 (sv) 2002-06-20 2002-06-20 Astrazeneca Ab New use
DE10234424A1 (de) 2002-07-29 2004-02-12 Bayer Ag Benzothiophen-, Benzofuran- und Indolharnstoffe
AU2003250322B2 (en) 2002-08-14 2010-01-21 Neurosearch A/S Novel quinuclidine derivatives and their use
JP2006501246A (ja) 2002-08-30 2006-01-12 メモリー・ファーマシューティカルズ・コーポレイション 神経変性疾患の治療において有用なアナバセイン誘導体
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
MXPA05003317A (es) 2002-09-25 2005-07-05 Memory Pharm Corp Indazoles, benzotiazoles y benzoisotiazoles asi como preparacion y usos de los mismos.
EP1592710A2 (en) 2003-02-14 2005-11-09 Memory Pharmaceutical Corporation Macaque alpha-7 nicotinic acetylcholine receptor and methods of use thereof
MXPA05006861A (es) 2003-02-27 2005-12-12 Neurosearch As Derivados arildiazabiciclicos novedosos.
US20050065178A1 (en) 2003-09-19 2005-03-24 Anwer Basha Substituted diazabicycloakane derivatives
CA2549965A1 (en) 2003-10-31 2005-05-19 Astrazeneca Ab Alkynes iii
EP1677790A1 (en) 2003-10-31 2006-07-12 AstraZeneca AB Alkynes ii
CA2549967A1 (en) 2003-10-31 2005-05-19 Astrazeneca Ab Alkynes i
FR2862647B1 (fr) 2003-11-25 2008-07-04 Aventis Pharma Sa Derives de pyrazolyle, procede de preparation et intermediaires de ce procede a titre de medicaments et de compositions pharmaceutiques les renfermant
US20050245531A1 (en) 2003-12-22 2005-11-03 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
DE602004010299T2 (de) 2003-12-22 2008-09-18 Memory Pharmaceuticals Corp. Indole, 1h-indazole, 1,2-benzisoxazole und 1,2-benzisothiazole und deren herstellung und anwendungen
EP1824848A1 (en) 2004-12-10 2007-08-29 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
ATE450263T1 (de) 2004-02-04 2009-12-15 Neurosearch As Diazabicyclische aryl-derivate als cholinerge rezeptor-modulatoren
EP1713810B1 (en) 2004-02-04 2010-12-29 NeuroSearch A/S Diazabicyclic aryl derivatives as nicotinic acetylcholine receptor ligands
EP1715867A4 (en) 2004-02-12 2009-04-15 Merck & Co Inc BIPYRIDYLAMIDE AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5
NZ550534A (en) 2004-03-25 2009-07-31 Memory Pharm Corp Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof
WO2006001894A1 (en) 2004-04-22 2006-01-05 Memory Pharmaceutical Corporation Indoles, 1h-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof
JP2007538011A (ja) 2004-05-07 2007-12-27 メモリー・ファーマシューティカルズ・コーポレイション １ｈ−インダゾール、ベンゾチアゾール、１，２−ベンゾイソキサゾール、１，２−ベンゾイソチアゾール、およびクロモン、ならびにそれらの調製および使用
JP2007538046A (ja) 2004-05-19 2007-12-27 ノイロサーチ アクティーゼルスカブ 新規なアザビシクロアリール誘導体
GB0412019D0 (en) 2004-05-28 2004-06-30 Novartis Ag Organic compounds
PE20060437A1 (es) 2004-06-18 2006-06-08 Novartis Ag COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
EP1802616B1 (en) 2004-10-15 2011-01-12 NeuroSearch A/S Novel azabicyclic aryl derivatives and their medical use
GB0424564D0 (en) * 2004-11-05 2004-12-08 Novartis Ag Organic compounds
WO2006051407A1 (en) 2004-11-15 2006-05-18 Pfizer Products Inc. Azabenzoxazoles for the treatment of cns disorders
WO2006051394A1 (en) 2004-11-15 2006-05-18 Pfizer Products Inc. Azabenzoxazoles for the treatment of cns disorders
CA2588961A1 (en) 2004-11-30 2006-06-08 Neurosearch A/S Novel diazabicyclic aryl derivatives as cholinergy ligands
RU2418797C2 (ru) 2004-12-22 2011-05-20 Мемори Фармасьютиклз Корпорейшн Лиганды никотинового рецептора альфа-7, их получение и применение
US20060142349A1 (en) * 2004-12-23 2006-06-29 Pfizer Inc Methods of modulating the activities of alpha-7 nicotinic acetylcholine receptor
WO2006087306A2 (en) 2005-02-16 2006-08-24 Neurosearch A/S Diazabicyclic aryl derivatives and their use as cholinergic ligands at the nicotinic acetylcholine receptors
AP2007004144A0 (en) 2005-03-31 2007-08-31 Pfizer Prod Inc Cyclopentapyridine and tetrahydroquinoline derivatives
FR2884822B1 (fr) 2005-04-22 2007-06-29 Aventis Pharma Sa Derives de triazines, leur preparation et leur application en therapeutique
US7585629B2 (en) 2005-04-22 2009-09-08 Cedars-Sinai Medical Center Compositions and methods for spinocerebellar ataxia
GB0508319D0 (en) 2005-04-25 2005-06-01 Novartis Ag Organic compounds
US8629163B2 (en) 2007-10-31 2014-01-14 University Of Kentucky Research Foundation Tetrakis-quaternary ammonium salts and methods for modulating neuronal nicotinic acteylcholine receptors
AU2006295397A1 (en) 2005-09-23 2007-04-05 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof
GB0521508D0 (en) 2005-10-21 2005-11-30 Novartis Ag Organic compounds
WO2007056582A1 (en) 2005-11-09 2007-05-18 Memory Pharmaceuticals Corporation 1 h-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof
CA2632642A1 (en) 2005-12-06 2007-06-14 Neurosearch A/S Novel diazabicyclic aryl derivatives and their medical use
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525672D0 (en) * 2005-12-16 2006-01-25 Novartis Ag Organic compounds
AU2006329007A1 (en) 2005-12-20 2007-06-28 Novartis Ag Nicotinic acid derivatives as modulators of metabotropic glutamate receptors
US7662965B2 (en) 2006-01-26 2010-02-16 Cornerstone Therapeutics, Inc. Anabaseine derivatives, pharmaceutical compositions and method of use thereof
WO2007085036A1 (en) 2006-01-26 2007-08-02 Medizinische Universität Wien Treatment of friedreich' s ataxia
AU2007216531A1 (en) 2006-02-14 2007-08-23 Neurosearch A/S Novel diazabicycloalkane derivatives and their medical use
CA2637531A1 (en) 2006-02-17 2007-08-30 Memory Pharmaceuticals Corporation Compounds having 5-ht6 receptor affinity
RU2008137604A (ru) 2006-02-22 2010-03-27 Арнольд МЮННИК (FR) Применение деферипрона и способ лечения и/или профилактики атаксии фридрейха, возникающей вследствие внутриклеточного нарушения обмена железа
WO2007110730A2 (en) * 2006-03-27 2007-10-04 Pfizer Products Inc. Varenicline standards and impurity controls
TW200813067A (en) 2006-05-17 2008-03-16 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
WO2007135122A1 (en) 2006-05-23 2007-11-29 Neurosearch A/S Novel 1,4-diaza-bicyclo[3.2.2]nonane derivatives and their medical use
EP2029607A1 (en) 2006-05-23 2009-03-04 NeuroSearch A/S Novel 8,10-diaza-bicycloý4.3.1¨decane derivatives and their medical use
US8158619B2 (en) 2006-05-30 2012-04-17 Neurosearch A/S 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl compounds and their medical use
WO2007138040A1 (en) 2006-05-30 2007-12-06 Neurosearch A/S Novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidinyl derivative and its medical use
WO2007146066A2 (en) 2006-06-06 2007-12-21 Critical Therapeutics, Inc. Novel piperazines, pharmaceutical compositions and methods of use thereof
US8178678B2 (en) 2006-06-16 2012-05-15 University Of Kentucky Research Foundation Bis-quaternary ammonium salts and methods for modulating neuronal nicotinic acetylcholine receptors
AU2007274710A1 (en) 2006-07-14 2008-01-24 Pfizer Products Inc. Tartrate salt of (7S)-7-[(5-fluoro-2-methyl-benzyl)oxy]-2-[(2R)-2-methylpiperazin-1-yl]-6,7-dihydro-5H-cyclopenta[b]pyridine
US8314119B2 (en) 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
TW200901974A (en) 2007-01-16 2009-01-16 Wyeth Corp Compounds, compositions, and methods of making and using them
US20080200471A1 (en) 2007-02-16 2008-08-21 Memory Pharmaceuticals Corporation 6' substituted compounds having 5-ht6 receptor affinity
EP2322168A1 (en) 2007-04-02 2011-05-18 Parkinson's Institute Methods and Compositions for Reduction of Side Effects of Therapeutic Treatments
CN101730680A (zh) 2007-05-24 2010-06-09 记忆医药公司 具有5-ht6受体亲和力的4’取代的化合物
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
AU2008286760A1 (en) 2007-08-15 2009-02-19 Memory Pharmaceuticals Corporation 3' substituted compounds having 5-HT6 receptor affinity
DK2217597T3 (da) 2007-10-01 2011-06-20 Comentis Inc Quinuclidin-4-ylmethyl-1h-indol-3-carboxylatderivater som alpha-7-nicotin-acetylcholin-receptor-ligander til behandling af Alzheimers sygdom
MX2010003155A (es) 2007-10-04 2010-04-01 Hoffmann La Roche Derivados de ciclopropil aril amida y uso de los mismos.
MX2010003156A (es) 2007-10-04 2010-04-01 Hoffmann La Roche Derivados de aril amida substituida con tetrazol y usos de los mismos.
WO2009066107A1 (en) 2007-11-21 2009-05-28 Astrazeneca Ab Use of a nicotinic receptor agonist
WO2009098576A1 (en) 2008-02-05 2009-08-13 Pfizer Inc. Pyridinyl amides for the treatment of cns and metabolic disorders
EP2250193B1 (en) 2008-02-19 2019-09-18 Myocept Inc. Postsynaptically targeted chemodenervation agents and their methods of use
WO2009146031A1 (en) 2008-03-31 2009-12-03 University Of South Florida Methods of treating disease-induced ataxia and non-ataxic imbalance
WO2009127678A1 (en) 2008-04-17 2009-10-22 Glaxo Group Limited Indoles as modulators of nicotinic acetylcholin receptor subtype alpha-71
WO2009128058A1 (en) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Psycho-pharmaceuticals
EP2300012A4 (en) 2008-05-23 2011-07-06 Univ South Florida METHOD FOR TREATING PERIPHERAL SENSORY NERVE LOSS WITH COMPOUNDS WITH NICOTIC ACIDYLCHOLINE RECEPTOR EFFECT
US20100016297A1 (en) 2008-06-24 2010-01-21 Memory Pharmaceuticals Corporation Alkyl-substituted 3' compounds having 5-ht6 receptor affinity
US20100022581A1 (en) 2008-07-02 2010-01-28 Memory Pharmaceuticals Corporation Pyrrolidine-substituted azaindole compounds having 5-ht6 receptor affinity
US20100029629A1 (en) 2008-07-25 2010-02-04 Memory Pharmaceuticals Corporation Acyclic compounds having 5-ht6 receptor affinity
US20100056531A1 (en) 2008-08-22 2010-03-04 Memory Pharmaceuticals Corporation Alkyl-substituted 3' compounds having 5-ht6 receptor affinity
US20100056491A1 (en) 2008-08-29 2010-03-04 Memory Pharmaceuticals Corporation 4'-amino cyclic compounds having 5-ht6 receptor affinity
EP2346833B1 (en) 2008-10-13 2013-03-27 F. Hoffmann-La Roche AG Diazonium-free method to make an indazole intermediate in the synthesis of bicyclic 5-(trifluormethoxy)-1h-3-indazolecarboxylic acid amides
US20110262407A1 (en) 2008-11-11 2011-10-27 Targacept, Inc. Treatment with alpha7 selective ligands
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
CN102802630A (zh) 2009-06-17 2012-11-28 塔加西普特公司 通过神经元烟碱受体配体逆转左旋多巴诱导的运动障碍
CN102573842A (zh) 2009-07-23 2012-07-11 诺瓦提斯公司 氮杂双环烷基衍生物或吡咯烷-2-酮衍生物的用途
JO3250B1 (ar) * 2009-09-22 2018-09-16 Novartis Ag إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101879919B1 (ko) * 2013-01-15 2018-07-18 노파르티스 아게 알파 7 니코틴성 아세틸콜린 수용체 작용물질의 용도

Also Published As

Publication number Publication date
US10537539B2 (en) 2020-01-21
CA2774801C (en) 2017-11-28
JP6178074B2 (ja) 2017-08-09
EP2480228A1 (en) 2012-08-01
JO3250B1 (ar) 2018-09-16
IL218299A0 (en) 2012-04-30
EA036742B1 (ru) 2020-12-15
MX359011B (es) 2018-09-12
TN2012000082A1 (en) 2013-09-19
NZ598316A (en) 2013-11-29
TW201116534A (en) 2011-05-16
MX2012003413A (es) 2012-04-30
US20120172346A1 (en) 2012-07-05
TWI558398B (zh) 2016-11-21
ZA201201066B (en) 2012-10-31
AU2010299967A1 (en) 2012-03-08
CL2012000702A1 (es) 2012-09-14
JP2016104743A (ja) 2016-06-09
ES2614930T3 (es) 2017-06-02
US11096916B2 (en) 2021-08-24
EA201200507A1 (ru) 2012-10-30
PH12012500554A1 (en) 2012-10-22
US20200108035A1 (en) 2020-04-09
US20210338621A1 (en) 2021-11-04
WO2011036167A1 (en) 2011-03-31
IL218299A (en) 2017-02-28
JP2013505282A (ja) 2013-02-14
CN110051670A (zh) 2019-07-26
SG178832A1 (en) 2012-04-27
CN102573830A (zh) 2012-07-11
BR112012006346A2 (pt) 2017-05-23
CA2774801A1 (en) 2011-03-31
MA33590B1 (fr) 2012-09-01
EP2480228B1 (en) 2016-11-16
AU2010299967B2 (en) 2014-03-13

Similar Documents

Publication Publication Date Title
US11096916B2 (en) Use of nicotinic acetylcholine receptor alpha 7 activators
US20140171448A1 (en) Use of nicotinic acetylcholine receptor alpha 7 activators
JP2015212277A (ja) 運動失調症の処置または予防のための、アザビシクロアルキル誘導体またはピロリジン−２−オン誘導体の使用
AU2012232711B2 (en) Combinations of alpha 7 nicotinic acetylcholine receptor activators and mGluR5 antagonists for use in dopamine induced dyskinesia in Parkinson's Disease
CN110051670B (zh) 烟碱乙酰胆碱受体α7激活剂的用途
HK1172557A (zh) 烟碱乙酰胆碱受体α7激活剂的用途
HK1167081B (en) Use of nicotinic acetylcholine receptor alpha 7 activators
HK1167081A (en) Use of nicotinic acetylcholine receptor alpha 7 activators

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20120321

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20150921

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20161128

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20171030

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20161128

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20171030

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20170530

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20150921

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20180305

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20180129

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20171030

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20170530

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20161128

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20150921

X601 Decision of rejection after re-examination
J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20180604

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20180305

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Patent event date: 20171030

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20200109

Appeal identifier: 2018101002388

Request date: 20180604

J301 Trial decision

Free format text: TRIAL NUMBER: 2018101002388; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20180604

Effective date: 20200109

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20200109

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20180604

Decision date: 20200109

Appeal identifier: 2018101002388